{"nctId":"NCT01082874","briefTitle":"PeriOperative ISchemic Evaluation-2 Trial","startDateStruct":{"date":"2010-07"},"conditions":["Cardiovascular Disease"],"count":10010,"armGroups":[{"label":"Active Clonidine and Active ASA","type":"EXPERIMENTAL","interventionNames":["Drug: Active Clonidine","Drug: Active ASA"]},{"label":"Active Clonidine and Placebo ASA","type":"EXPERIMENTAL","interventionNames":["Drug: Active Clonidine","Drug: Placebo ASA"]},{"label":"Placebo Clonidine and Active ASA","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo Clonidine","Drug: Active ASA"]},{"label":"Placebo Clonidine and Placebo ASA","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Clonidine","Drug: Placebo ASA"]}],"interventions":[{"name":"Active Clonidine","otherNames":["CATAPRES, CATAPRES-TTS"]},{"name":"Placebo Clonidine","otherNames":[]},{"name":"Active ASA","otherNames":["ASPIRIN"]},{"name":"Placebo ASA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Are undergoing noncardiac surgery;\n2. Are ≥ 45 years of age;\n3. Are expected to require at least an overnight hospital admission after surgery; AND\n4. Fulfill one or more of the following 5 criteria:\n\n   * History of coronary artery disease\n   * History of peripheral vascular disease\n   * History of stroke\n   * Undergoing major vascular surgery\n   * Any 3 of the following 9 criteria:\n\n     * undergoing major surgery (i.e. intraperitoneal, intrathoracic, retroperitoneal or major orthopedic surgery\n     * history of congestive heart failure\n     * transient ischemic attack\n     * diabetes and currently taking an oral hypoglycemic agent or insulin\n     * age ≥ 70 years\n     * hypertension\n     * serum creatinine \\> 175 µmol/L (\\> 2.0 mg/dL)\n     * history of smoking within 2 years of surgery\n     * undergoing urgent/emergent surgery\n\nExclusion Criteria:\n\n1. Consumption of ASA within 72 hours prior to surgery\n2. Hypersensitivity or known allergy to ASA or clonidine\n3. Systolic blood pressure \\< 105 mm Hg\n4. Heart rate \\< 55 beats per minute in a patient who does not have a permanent pacemaker\n5. Second or third degree heart block without a permanent pacemaker\n6. Active peptic ulcer disease or gastrointestinal bleeding within previous 6 weeks\n7. Intracranial hemorrhage documented by neuro-imaging, in the 6 months prior to randomization. This does not include petechial hemorrhagic transformation of a primary ischemic stroke\n8. Subarachnoid hemorrhage or epidural hematoma unless the event occurred more than 6 months prior to randomization and the offending aneurysm or arterial lesion has been repaired\n9. Drug-eluting coronary stent in the year prior to randomization\n10. Bare-metal coronary stent in the 6 weeks prior to randomization\n11. Thienopyridine (e.g., clopidogrel, ticlopidine, prasugrel) or ticagrelor within 72 hours prior to surgery; or intent to restart a thienopyridine or ticagrelor during the first 7 days post-op; or currently taking an alpha-2 agonist, alpha methyldopa, monoamine oxidase inhibitors or reserpine;\n12. Planned use - during the first 3 days after surgery - therapeutic dose anticoagulation or a therapeutic subcutaneous or intravenous antithrombotic agent\n13. Undergoing intracranial surgery, carotid endarterectomy, or retinal surgery\n14. Not consenting to participate in POISE-2 prior to surgery\n15. Previously enrolled in POISE-2 Trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of All-cause Mortality and Nonfatal MI","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"194","spread":null},{"groupId":"OG002","value":"178","spread":null},{"groupId":"OG003","value":"161","spread":null}]}]}]},{"type":"PRIMARY","title":"All-cause Mortality and Nonfatal MI","description":null,"classes":[]},{"type":"SECONDARY","title":"Composite of All-cause Mortality, Nonfatal MI, and Nonfatal Stroke","description":null,"classes":[]},{"type":"SECONDARY","title":"Individual Secondary Outcomes","description":"All-cause mortality, vascular mortality, MI, nonfatal cardiac arrest, cardiac revascularization procedure, pulmonary emboli, deep venous thrombosis, clinically important atrial fibrillation, amputation, peripheral arterial thrombosis, infection/sepsis, rehospitalization for vascular reasons, length of hospital stay, length of intensive care unit / cardiac care unit (ICU/CCU) stay, and new acute renal failure requiring dialysis.","classes":[]},{"type":"SECONDARY","title":"Composite Outcome by ASA Stratum","description":"Composite outcome of all-cause mortality, nonfatal MI, cardiac revascularization procedure, nonfatal pulmonary emboli, and nonfatal deep venous thrombosis.","classes":[]},{"type":"SECONDARY","title":"Safety Outcomes in ASA Trial","description":"Stroke, congestive heart failure, life-threatening bleeding, and major bleeding.","classes":[]},{"type":"SECONDARY","title":"Safety Outcomes in Clonidine Trial","description":"Stroke, clinically important hypotension, clinically important bradycardia, and congestive heart failure.","classes":[]},{"type":"SECONDARY","title":"Composite Outcome at 1 Year","description":"All-cause mortality, nonfatal MI, and nonfatal stroke.","classes":[]},{"type":"SECONDARY","title":"Individual Secondary Outcomes at 1 Year","description":"All cause mortality, vascular mortality, MI, nonfatal cardiac arrest, cardiac revascularization procedure, stroke, pulmonary emboli, deep venous thrombosis, amputation, peripheral arterial thrombosis, new diagnosis of cancer, diagnosis of recurrent cancer and rehospitalization for vascular reason.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":2499},"commonTop":[]}}}